Evidence map›Paper›PMID 36255237›Full record

ArticlemBio2022

A Fungal Sterylglucosidase at the Intersection of Virulence, Host Immunity, and Therapeutic Development.

Robert A Cramer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert A CramerGeisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0001-5503-5006
Dartmouth College · US

Funding

Evolution of Aspergillus fumigatus virulenceR01AI130128 · NIAID · DARTMOUTH COLLEGE · PI Robert Andrew Cramer · 2017 to 2026
$4.5M
Environmental Oxygen Transitions and Aspergillosis Disease ProgressionR01AI146121 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2019 to 2023
$2.6M
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease InhibitionR33AI140878 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2021 to 2023
$1.3M
NIAID NIH HHS R01 AI130128NIAID NIH HHS R01 AI146121NIAID NIH HHS R33 AI140878
6 · The paper itself

Abstract

Human fungal infections (mycoses) cause significant morbidity and mortality in high-risk populations. Contemporary antifungal therapies rely heavily on three classes of antifungal drugs, and to date, no fungal vaccine is in clinical use for invasive mycosis. A major gap in knowledge related to fungal vaccine development is identifying lasting mechanisms of protective immunity in immunocompromised individuals. Recent studies in Cryptococcus neoformans and now Aspergillus fumigatus have identified a fungal sterylglucosidase essential for pathogenesis and virulence in murine models of mycoses. Fungal strains deficient in this sterylglucosidase can surprisingly also induce substantial immune-mediated protection against subsequent challenge with wild-type strains in multiple immunocompromised murine models of mycoses. Here, I discuss the implications and future directions of these exciting and impactful results.

Indexed as

CryptococcosisCryptococcus neoformansMycosesAnimalsAntifungal AgentsAspergillus fumigatusHumansMiceVirulenceAntifungal AgentsAspergillus fumigatusfungal immunityfungal vaccineimmunocompromisedinvasive aspergillosissterylglucosidase

Identifiers

PMID36255237
PMCPMC9765442
OpenAlexW4306734384

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.